
简介:
- 作者: Yiyun Lou, Jiaoyao Ma, Yangnan Hu, Xiaoying Yao, Yaoqian Liu, Mingxuan Wu, Gaogan Jia, Yan Chen, Renjie Chai, Mingyu Xia, Wenyan Li
- 杂志: Advanced Science
- Doi: https://www.doi.org/10.1002/advs.202309617
- 出版日期: 2024 Jul 18
论文中使用的产品/服务
Quotation shows PackGene:The virus used for this study were AAV2/DJ-CMV-mCherry (Obio Technology Corp) and AAV2/9-hSyn-EGFP (PackGene Biotech). Viral titer ≥ 1E+13 GC mL−1.
Research Field:peripheral and central auditory systems
AAV Serotype:AAV2
Targeted organ:incubation
Animal or cell line strain:SGN and ACN Single Cells
摘要
The physiological interactions between the peripheral and central auditory systems are crucial for auditory information transmission and perception, while reliable models for auditory neural circuits are currently lacking. To address this issue, mouse and human neural pathways are generated by utilizing a carbon nanotube nanofiber system. The super-aligned pattern of the scaffold renders the axons of the bipolar and multipolar neurons extending in a parallel direction. In addition, the electrical conductivity of the scaffold maintains the electrophysiological activity of the primary mouse auditory neurons. The mouse and human primary neurons from peripheral and central auditory units in the system are then co-cultured and showed that the two kinds of neurons form synaptic connections. Moreover, neural progenitor cells of the cochlea and auditory cortex are derived from human embryos to generate region-specific organoids and these organoids are assembled in the nanofiber-combined 3D system. Using optogenetic stimulation, calcium imaging, and electrophysiological recording, it is revealed that functional synaptic connections are formed between peripheral neurons and central neurons, as evidenced by calcium spiking and postsynaptic currents. The auditory circuit model will enable the study of the auditory neural pathway and advance the search for treatment strategies for disorders of neuronal connectivity in sensorineural hearing loss.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
